XORTX Therapeutics Inc. Common Stock (XRTX) Stock Price

XRTXStock

$1.24−67.95%52W

Market Cap$2.25M

P/E—

PEG Ratio—

Div yield—

Beta0.03

XRTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.27%

Price vs S&P 500 (4W)8.69%

VGM Score64.86

Book Value / Share (Quarterly)$0.92

P/TBV (Annual)2.91x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-20.19%

Cash Flow / Share (Quarterly)$-1.93

Price vs S&P 500 (YTD)-27.48%

Gross Margin (TTM)21.01%

Net Profit Margin (TTM)-2.60%

EPS (TTM)$-2.65

10-Day Avg Trading Volume0.00M

EPS Excl Extra (TTM)$-2.65

EPS (Annual)$-2.81

ROI (Annual)-125.19%

Gross Margin (Annual)21.01%

Cash / Share (Quarterly)$0.18

ROA (Last FY)-98.99%

EBITD / Share (TTM)$-2.71

ROE (5Y Avg)-78.68%

Operating Margin (TTM)-0.27%

Cash Flow / Share (Annual)$-2.03

P/B Ratio3.41x

P/B Ratio (Quarterly)3.04x

Net Income / Employee (Annual)$-885,400

Net Interest Coverage (TTM)-131.30x

ROA (TTM)-106.58%

EPS Incl Extra (Annual)$-2.81

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)0.80x

3-Month Avg Trading Volume0.00M

52-Week Price Return-67.95%

Revenue / Employee (TTM)$271,440,000

Tangible BV / Share (Quarterly)$0.79

P/S Ratio (Annual)0.01x

Asset Turnover (Annual)2.01x

52-Week High$9.85

EPS Excl Extra (Annual)$-2.81

CapEx CAGR (5Y)38.81%

26-Week Price Return11.93%

Quick Ratio (Annual)2.07x

13-Week Price Return-9.89%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.86x

Enterprise Value$4.15M

Asset Turnover (TTM)1.88x

Revenue / Employee (Annual)$271,440,000

Inventory Turnover (Annual)4.23x

Pretax Margin (Annual)-0.24%

Cash / Share (Annual)$0.62

3-Month Return Std Dev52.29%

Net Income / Employee (TTM)$-922,000

ROE (Last FY)-127.43%

Net Interest Coverage (Annual)-0.77x

EPS Basic Excl Extra (Annual)$-2.81

P/FCF (TTM)8.32x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-2.65

Receivables Turnover (Annual)15.35x

ROI (TTM)-146.27%

P/S Ratio (TTM)0.01x

Revenue / Share (Annual)$29.65

Tangible BV / Share (Annual)$1.36

Price vs S&P 500 (52W)-67.56%

Year-to-Date Return-17.14%

5-Day Price Return11.93%

EPS Normalized (Annual)$-2.81

ROA (5Y Avg)-57.85%

Net Profit Margin (Annual)-2.60%

Month-to-Date Return12.32%

Cash Flow / Share (TTM)$-4.98

EBITD / Share (Annual)$-3.32

Operating Margin (Annual)-0.27%

LT Debt / Equity (Annual)0.13x

ROI (5Y Avg)-77.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.65

P/TBV (Quarterly)3.55x

P/B Ratio (Annual)2.66x

Pretax Margin (TTM)-0.24%

Book Value / Share (Annual)$1.50

Price vs S&P 500 (13W)-11.28%

Beta0.03x

P/FCF (Annual)55.68x

Revenue / Share (TTM)$29.55

ROE (TTM)-150.08%

52-Week Low$2.42

vGradeB

mGradeC

vgmGradeB

XRTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q4 2025	Feb 27, 2026	-$1.58	-$0.45	+71.47%(+$1.13)
Q3 2025	Nov 15, 2025	-$1.58	-$1.02	+35.22%(+$0.56)

XRTX Analyst Recommendations

Dec 2023

Jan 2024

Feb 2024

Mar 2024

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
XRTXXORTX Therapeutics Inc. Common Stock	B	—	C	0.0x	—	21.0%	—	$1.24
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About XORTX Therapeutics Inc. Common Stock

XORTX Therapeutics is a clinical-stage biotechnology company developing therapies for progressive kidney disease by targeting purine and uric acid metabolism. The company is advancing three therapeutic candidates for rare kidney disease indications including ADPKD and Type 2 Diabetic Nephropathy, as well as acute kidney injury associated with respiratory infections. The company aims to slow or reverse chronic kidney disease progression and explore additional indications leveraging its intellectual property.